EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma

Yan Zhou, Yuyue Hou, Shengqing Hu, Chenxi Zhu, Mingjie Zhang, Yuangu Gao, Yajing Zhang, Ji Li, Wei Cao, Zairong Gao, Jie Tan, Xiaotian Xia

Frontiers in Endocrinology · 19.05.2026 · 17

DOI: 10.3389/fendo.2026.1836784 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Frontiers in Endocrinology, online erschienen am 19.05.2026. Verfasst von Yan Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Cancer, Papillary, Thyroid Neoplasms, Obesity. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objective Obesity is a heterogeneous metabolic condition that may influence tumor biology and therapeutic outcomes. However, factors associated with the response to postoperative radioactive iodine ( 131 I) therapy in obese patients with papillary thyroid carcinoma (PTC) remain insufficiently understood. This study aimed to identify clinical and metabolic factors associated with treatment response in this population.

Methods

This retrospective observational study included obese patients with PTC who underwent postoperative 131 I therapy between January 2020 and December 2023. Clinical, biochemical, imaging, treatment, and follow-up data were collected from electronic medical records. Treatment response at the most recent follow-up was classified as excellent response (ER) or non-excellent response (NER) according to the 2025 American Thyroid Association (ATA) guidelines. Logistic regression analysis was performed to identify factors associated with treatment response, and receiver operating characteristic (ROC) analysis was used to evaluate predictive performance.

Results

A total of 219 obese patients with PTC were included, with a median follow-up of 31.00 months. At the last follow-up, 91 patients (41.6%) achieved ER. In multivariable analysis, higher high-density lipoprotein (HDL) levels were independently associated with an increased likelihood of ER (OR = 22.891, 95% CI: 2.644-198.206, P = 0.004), whereas higher pre-ablation stimulated thyroglobulin (sTg) levels were independently associated with a lower likelihood of ER (OR = 0.793, 95% CI: 0.719-0.876, P < 0.001). Triglycerides (TG) also showed a weaker association with treatment response (OR = 0.662, 95% CI: 0.442-0.991, P = 0.045). Among the individual indicators, sTg showed the best discriminatory performance (AUC = 0.767), followed by HDL (AUC = 0.672) and TG (AUC = 0.624). A combined model incorporating HDL and sTg improved predictive performance (AUC = 0.822).

Conclusion

In obese patients with PTC who underwent postoperative 131 I therapy, pre-ablation sTg and HDL were independently associated with treatment response, whereas TG showed a weaker association. The combination of HDL and sTg provided better discriminatory performance than either marker alone. These findings suggest that combining metabolic indicators with conventional tumor-related markers may improve individualized evaluation of treatment response in obese patients with PTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid Cancer, PapillaryThyroid NeoplasmsObesityHumansFemaleRetrospective StudiesMaleMiddle AgedAdultTreatment OutcomeChinaEast Asian People

Stichwörter der Autor:innen

high-density lipoproteinobesitypapillary thyroid carcinomaradioactive iodine therapystimulated thyroglobulintreatment response

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
  • Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China.
  • Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • Natural Science Foundation of Hubei Province

Zitieren

APA

Zhou, Y., Hou, Y., Hu, S., Zhu, C., Zhang, M., Gao, Y., Zhang, Y., Li, J., Cao, W., Gao, Z., Tan, J., & Xia, X. (2026). Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1836784

Vancouver

Zhou Y, Hou Y, Hu S, Zhu C, Zhang M, Gao Y, et al. Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1836784

BibTeX
@article{Zhou2026,
  author = {Zhou, Yan and Hou, Yuyue and Hu, Shengqing and Zhu, Chenxi and Zhang, Mingjie and Gao, Yuangu and Zhang, Yajing and Li, Ji and Cao, Wei and Gao, Zairong and Tan, Jie and Xia, Xiaotian},
  title = {Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1836784}
}
Kostenlos starten →